Contact Us

Defective Drugs
*    Denotes required field.

Title 

   * First Name 

   * Last Name 

   * Email 

   * Phone 

Cell Phone 

Office Phone 

Street Address 

Apartment/Suite 

Zip Code 

City 

State 

Please provide the best method and time to contact you:

Date of birth : 

Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

Other Info: 

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review all.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

DEFECTIVE DRUGS

Defective Drugs
AddThis Social Bookmark Button

Defective Drug Side Effects Lawsuits Lawyer

Parker Waichman LLP is a leading personal injury law firm with experienced defective drug attorneys on staff. We are currently one of the leading law firms dealing with pharmaceutical litigation cases and are evaluating cases involving defective drug lawsuits throughout the United States.

Prescription drugs with deadly or dangerous side effects are often rushed to market without adequate testing and often people are injured or die before they are identified by the FDA as having dangerous side effects that outweigh whatever benefits they may have.

When an FDA classification leads to a drug recall and when an injury occurs, a lawsuit is filed and is based upon personal injury law. Drug recall lawsuits will usually fall into such categories as drug injury law, product liability or medical malpractice lawsuits against drug companies

If you or a loved one have been injured as a result of a prescription drug, Parker Waichman LLP urges you to contact us by completing the form at right or call us at 1-800-LAW-INFO (1-800-529-4636).

To view more information involving a specific defective drug, drug recall, or drug lawsuits, please click on one of the links listed below. If you seek an experienced defective drug lawyer, please fill out the form at the right for a free case evaluation by one of our qualified attorneys.

If the defective drug you are looking for is not listed in the links below, please Visit our Defective Drugs Archives Page for additional articles about defective drug lawsuits that Parker Waichman LLP has defended for our clients.

Tags:  

Defective Drugs

Defective Drugs NewsRSS Feed

BMJ Study Find SSRIs During Pregnancy Double Risk of PPHN

Jan 13, 2012 | Parker Waichman LLP
A new study published in the British Medical Journal has provided compelling new evidence of a connection between selective serotonin reuptake...

FDA Yaz, Yasmin Advisors Had Relationships with Bayer

Jan 11, 2012 | Parker Waichman LLP
Last month, an advisory panel for the U.S. Food & Drug Administration (FDA) voted to recommend by a four vote (15-11) margin that the benefits of...

Pradaxa Clinical Trial Analysis Sees Higher Heart Attack Risk

Jan 10, 2012 | Parker Waichman LLP
A new study is raising more concerns about Pradaxa. According to researchers from the Cleveland Clinic, people taking Pradaxa may be at a higher risk...

Mediation Bid Postpones First Yaz, Yasmin Lawsuit Trial

Jan 5, 2012 | Parker Waichman LLP
The much anticipated first bellwether trial in the Yaz and Yasmin multidistrict litigation won't be starting next week after all.  The trial was...

Proscar, Propecia Litigation Heating UP

Dec 21, 2011 | Parker Waichman LLP
The litigation surrounding Merck's Proscar and Propecia medications continues to grow, with several plaintiffs seeking mass tort status for their...

Heart Risks Garner New Restrictions for Multaq

Dec 20, 2011 | Parker Waichman LLP
The U.S. Food & Drug Administration (FDA) has warned that Multaq should not be used to treat temporary atrial fibrillation because it may place...

Pfizer Settles More Premarin, Prempro Breast Cancer Lawsuits

Dec 20, 2011 | Parker Waichman LLP
Nearly 5,000 of the 10,000 breast cancer lawsuits Pfizer faced over its Prempro and Premarin hormone therapy drugs have been settled.  According...

Health Canada Revises Bisphosphonate Labels with Fracture Warning

Dec 20, 2011 | Parker Waichman LLP
Health Canada has announced that its review of bisphosphonates has shown a slightly increased risk of atypical thigh fractures among people who use...

Medtronic Infuse Concerns Prompt Questions from Senators

Dec 19, 2011 | Parker Waichman LLP
Medtronic Inc. is taking more heat over its controversial Infuse bone graft product.  Now, three U.S. Senators are asking questions about...

Medtronic Infuse Shareholder Class Action Lawsuit Certified

Dec 13, 2011 | Parker Waichman LLP
Medtronic, Inc. got more bad news on the Infuse front yesterday, when a federal judge granted class action status to an investor shareholder lawsuit...

Yaz, Yasmin Blood Clot Risk Warnings Need to be Stronger, FDA Advisors Say

Dec 9, 2011 | Parker Waichman LLP
Two U.S. Food & Drug Administration (FDA) committees voted overwhelmingly yesterday to recommend stronger label warnings for Yaz, Yasmin and...

Medtronic Discloses California Infuse Investigation

Dec 8, 2011 | Parker Waichman LLP
Medtronic continues to be plagued by investigations into its controversial Infuse bone growth product. According to its most recent 10-Q filing with...